Company Focus
Alnylam Pharmaceuticals
Latest Alnylam Pharmaceuticals News
Biotechnology
USA-based RNAi therapeutics company Alnylam Pharmaceuticals reported second-quarter revenues of $1.29 billion, up 67% year on year, alongside adjusted earnings of $1.84 per share, a sharp turnaround from $0.28 a year earlier. Even so, the top line landed just short of the roughly $1.32 billion that analysts had penciled in. 31 July 2026
Related News
Insights
Company Spotlight
A Danish clinical-stage TechBio company using its proprietary AI-Immunology platform to design therapeutic vaccines for cancer and infectious disease, with a pipeline spanning personalized, off-the-shelf, and bacterial vaccine candidates.
Latest News & Features of interest to Alnylam Pharmaceuticals
Biotechnology
US biotech major Regeneron Pharmaceuticals has voluntarily terminated an early-stage study of REGN7041, an experimental anti-CD3 monoclonal antibody being developed for active non-infectious uveitis affecting the back of the eye, after judging that the benefit-risk profile no longer supported continuing. 18 August 2026
Pharmaceutical
USA-based ophthalmic diseases specialist EyePoint Pharmaceuticals today announced top-line results from LUGANO, the first pivotal Phase III clinical trial for Duravyu (vorolanib intravitreal insert) for the treatment of wet age-related macular degeneration (wet AMD). 17 August 2026
Biotechnology
Danish clinical-stage techbio Evaxion, which is developing novel vaccines with its pioneering AI-Immunology platform, is expanding its pipeline of cancer vaccine programs with EVX-05 against the deadly brain cancer glioblastoma. The company’s shares moved up 4.8% to $3.50 in pre-market activity on the news. 17 August 2026
Pharmaceutical
US pharma major Bristol Myers Squibb was hit with adverse developments on two separate legal fronts this month, both stemming from its 2019 acquisition of Celgene and its cardiovascular franchise. 17 August 2026
Biosimilars
Swiss affordable medicines company Sandoz today announced a major development, manufacturing and commercialization collaboration agreement with Shanghai Henlius Biotech, marking another significant step to broaden patient access to high-quality biosimilar medicines worldwide. 17 August 2026
Biotechnology
US clinical-stage biotech Neumora Therapeutics on Friday announced that Joshua Pinto has been appointed as chief executive (CEO) and a member of the board of directors. 17 August 2026
Pharmaceutical
Deal-making news last week including Spanish dermatology specialist Almirall entering into a research collaboration with China’s CrystalO Biopharma. Sentynl entered a deal to license lung disease candidate alvelestat from Mereo BioPharma, which could earn the latter nearly half a billion dollars. Also, PTC Therapeutics is acquiring Fabry disease candidate ST-920 from Sangamo competitive bankruptcy auction. On the M&A front, Jazz Pharmaceuticals announced an $820 million upfront bid to acquire Actio Biosciences and its investigational epilepsy treatment ABS-1230. 16 August 2026
Biotechnology
US metabolic health company Skye Bioscience and Redx Pharma, a UK based, privately-held clinical-stage biotechnology company focused on developing novel, small molecule, targeted medicines for fibrotic disease, have entered into a definitive transaction agreement. 14 August 2026
Biotechnology
USA-based Khartis Therapeutics has come out of stealth with $95 million raised to date and a plan to develop an oral pill for thyroid eye disease (TED), a market currently served only by antibodies given by intravenous infusion. The San Diego biotech announced the debut on Thursday. 14 August 2026
Pharmaceutical
The European Medicines Agency (EMA) has validated the marketing authorization application for PF-07307405, the six-valent Lyme disease vaccine candidate from US pharma major Pfizer and French vaccine specialist Valneva, and has begun its assessment. No human Lyme vaccine is approved anywhere at present. 14 August 2026
Latest In Brief for Alnylam Pharmaceuticals
Pharmaceutical
Israel-based generics giant Teva Pharmaceutical Industries and France’s Medincell announced that the US Food and Drug Administration has accepted the New Drug Application for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults. 21 February 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze